

Catalog# BP- 50524

Burosumab Biosimilar (Human FGF23 Monoclonal Antibody)

Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia.

Product Details	
CAS No.	1610833-03-8
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Clone	Burosumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human FGF23 protein
Purity	>95%
Molecular Weight	144.08 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.